Compare · BSX vs RCEL
BSX vs RCEL
Side-by-side comparison of Boston Scientific Corporation (BSX) and Avita Medical Inc. (RCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and RCEL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.16B, about 560.9x RCEL ($128.6M).
- Over the past year, BSX is down 51.3% and RCEL is down 31.8% - RCEL leads by 19.5 points.
- RCEL has been more active in the news (15 items in the past 4 weeks vs 12 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 7 for RCEL).
- Company
- Boston Scientific Corporation
- Avita Medical Inc.
- Price
- $48.71+0.31%
- $4.21+0.24%
- Market cap
- $72.16B
- $128.6M
- 1M return
- -13.91%
- +0.96%
- 1Y return
- -51.31%
- -31.82%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 15
- Recent ratings
- 25
- 7
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Avita Medical Inc.
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest RCEL
- SEC Form 424B5 filed by Avita Medical Inc.
- Avita Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Director Woody Joseph Fralin bought $40,949 worth of shares (10,000 units at $4.09), increasing direct ownership by 12% to 92,761 units (SEC Form 4)
- Director Mcnamara Robert was granted 22,214 shares, increasing direct ownership by 26% to 108,985 units (SEC Form 4)
- Director Woody Joseph Fralin was granted 62,761 shares, increasing direct ownership by 314% to 82,761 units (SEC Form 4)
- Director Tarnoff Michael E was granted 48,464 shares (SEC Form 4)
- Director Cook Jeremy Curnock was granted 22,214 shares, increasing direct ownership by 56% to 62,050 units (SEC Form 4)
- Director Crowe Suzanne was granted 22,214 shares, increasing direct ownership by 47% to 69,148 units (SEC Form 4)
- Director Reed Jan Stern was granted 22,214 shares, increasing direct ownership by 44% to 73,225 units (SEC Form 4)
- Director Woody Joseph Fralin bought $84,936 worth of shares (20,000 units at $4.25) (SEC Form 4)